Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3737)	2/4/1998 7:56:00 PM
From: Ariella	Read Replies (2) \| Respond to of 6136

To all: AOL Health channel carries Assoc. Press story mentioning AGPH tonight. aol://4344:30.HEALTHY.5273065.561409129 (Keyword: Health) Story discusses Viracept and other PIs; also notes competitive drug due out in near future. Generally supportive, but notes which profile of patients do not do well on PIs. Excerpt: <<Protease inhibitors may not be an essential ingredient of the cocktail. Studies of abacavir, Glaxo Wellcome's experimental nucleoside analogue, suggest it may be combined with two older medicines in the same category to suppress HIV. This could be an option for those whose virus has grown resistant to protease inhibitors. >> Could someone knowledgable on such things shed light on the above comment and its impact, if any, on AGPH? Thanks, Ariella